Venetoclax Plus Gilteritinib Is Effective in Preclinical Models of FLT3-Mutant BCL11B-a Lineage-Ambiguous Leukemia

By
Emily Salmini
-
0
45
Scientists investigated the efficacy of B-cell lymphoma 2 (BCL-2) and FMS-like tyrosine kinase 3 (FLT3) inhibition with venetoclax and gilteritinib, respectively, in preclinical models of BCL11B-a leukemia.
[Blood]
Abstract